$CVSI
CV Sciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127040 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $3.865M
YoY Change -5.48%
Cost Of Revenue $2.087M
YoY Change -7.08%
Gross Profit $1.778M
YoY Change -3.53%
Gross Profit Margin 46.0%
Selling, General & Admin $2.090M
YoY Change -6.7%
% of Gross Profit 117.55%
Research & Development $29.00K
YoY Change -27.5%
% of Gross Profit 1.63%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.119M
YoY Change -7.06%
Operating Profit -$341.0K
YoY Change -21.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$115.0K
YoY Change 1050.0%
Pretax Income -$456.0K
YoY Change 2.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$456.0K
YoY Change 2.01%
Net Earnings / Revenue -11.8%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 184.3M 180.7M
Diluted Shares Outstanding 182.3M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $979.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $5.020M
Prepaid Expenses
Receivables $422.0K
Other Receivables
Total Short-Term Assets $6.748M
YoY Change -20.14%
LONG-TERM ASSETS
Property, Plant & Equipment $490.0K
YoY Change 22.81%
Goodwill $815.0K
YoY Change
Intangibles $103.0K
YoY Change -58.96%
Long-Term Investments
YoY Change
Other Assets $154.0K
YoY Change -55.75%
Total Long-Term Assets $1.643M
YoY Change 37.72%
TOTAL ASSETS
Total Short-Term Assets $6.748M
Total Long-Term Assets $1.643M
Total Assets $8.391M
YoY Change -12.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.886M
YoY Change -28.1%
Accrued Expenses $3.422M
YoY Change 3.35%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.143M
YoY Change 1.35%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $38.00K
YoY Change -58.7%
Total Long-Term Liabilities $38.00K
YoY Change -58.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.143M
Total Long-Term Liabilities $38.00K
Total Liabilities $6.200M
YoY Change 0.58%
SHAREHOLDERS EQUITY
Retained Earnings -$86.30M
YoY Change 3.11%
Common Stock $18.00K
YoY Change 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.191M
YoY Change
Total Liabilities & Shareholders Equity $8.391M
YoY Change -12.98%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$456.0K
YoY Change 2.01%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
111000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2090000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2240000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6942000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7154000
CY2024Q3 cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
0
CY2023Q3 cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
0
cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
0
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001510964
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
cvsi Gain Loss In Fair Value Of Contingent Consideration Liabilities
GainLossInFairValueOfContingentConsiderationLiabilities
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-54677
dei Entity Registrant Name
EntityRegistrantName
CV Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
80-0944970
dei Entity Address Address Line1
EntityAddressAddressLine1
9530 Padgett Street, Suite 107
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92126
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
290-2157
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
184263663
CY2024Q3 us-gaap Cash
Cash
979000
CY2023Q4 us-gaap Cash
Cash
1317000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
422000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
431000
CY2024Q3 us-gaap Inventory Net
InventoryNet
5020000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5655000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
327000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
535000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
6748000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7938000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
490000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
81000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
167000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
103000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
78000
CY2024Q3 us-gaap Goodwill
Goodwill
815000
CY2023Q4 us-gaap Goodwill
Goodwill
342000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
154000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2024Q3 us-gaap Assets
Assets
8391000
CY2023Q4 us-gaap Assets
Assets
9200000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1886000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2309000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3422000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3422000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
92000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130000
CY2024Q3 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
743000
CY2023Q4 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
254000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6143000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6115000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
19000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
19000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
38000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
105000
CY2024Q3 us-gaap Liabilities
Liabilities
6200000
CY2023Q4 us-gaap Liabilities
Liabilities
6297000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
790000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
790000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184264000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184264000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161678000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161678000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
18000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
88409000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87464000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86255000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84587000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2191000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2903000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8391000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9200000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3865000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4089000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12203000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
2087000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
2246000
us-gaap Cost Of Revenue
CostOfRevenue
6330000
us-gaap Cost Of Revenue
CostOfRevenue
6860000
CY2024Q3 us-gaap Gross Profit
GrossProfit
1778000
CY2023Q3 us-gaap Gross Profit
GrossProfit
1843000
us-gaap Gross Profit
GrossProfit
5491000
us-gaap Gross Profit
GrossProfit
5343000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40000
cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
-6171000
CY2024Q3 cvsi Operating Costs And Expenses Net
OperatingCostsAndExpensesNet
2119000
CY2023Q3 cvsi Operating Costs And Expenses Net
OperatingCostsAndExpensesNet
2280000
cvsi Operating Costs And Expenses Net
OperatingCostsAndExpensesNet
7035000
cvsi Operating Costs And Expenses Net
OperatingCostsAndExpensesNet
1094000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-341000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-437000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1544000
us-gaap Operating Income Loss
OperatingIncomeLoss
4249000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-115000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-118000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-275000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-456000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-447000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1662000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3974000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-456000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-447000
us-gaap Net Income Loss
NetIncomeLoss
-1668000
us-gaap Net Income Loss
NetIncomeLoss
3971000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182261000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182261000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154604000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154604000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172671000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172671000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153112000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153112000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-456000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-447000
us-gaap Net Income Loss
NetIncomeLoss
-1668000
us-gaap Net Income Loss
NetIncomeLoss
3971000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
9000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-435000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-447000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1659000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3971000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2903000
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
62000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-628000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2362000
CY2024Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
700000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-584000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2508000
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
31000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
87000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-456000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2191000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-777000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
118000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
5706000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5047000
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1288000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3894000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-447000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3479000
us-gaap Net Income Loss
NetIncomeLoss
-1668000
us-gaap Net Income Loss
NetIncomeLoss
3971000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
220000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000
us-gaap Share Based Compensation
ShareBasedCompensation
154000
us-gaap Share Based Compensation
ShareBasedCompensation
185000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
117000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
112000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
86000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80000
cvsi Gain Loss In Fair Value Of Contingent Consideration Liabilities
GainLossInFairValueOfContingentConsiderationLiabilities
188000
cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
0
cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
-6171000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
236000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
368000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-19000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-103000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-689000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-834000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-208000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2778000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-570000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-69000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-697000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2367000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
6000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
900000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
325000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1117000
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
203000
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
218000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
367000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1335000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-338000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1032000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1317000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
611000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
979000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1643000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
us-gaap Income Taxes Paid
IncomeTaxesPaid
6000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
cvsi Services Paid With Common Stock
ServicesPaidWithCommonStock
92000
cvsi Services Paid With Common Stock
ServicesPaidWithCommonStock
100000
cvsi Debt Issuance Cost For Note Payable
DebtIssuanceCostForNotePayable
284000
cvsi Debt Issuance Cost For Note Payable
DebtIssuanceCostForNotePayable
0
cvsi Working Capital Adjustment Due From Seller
WorkingCapitalAdjustmentDueFromSeller
34000
cvsi Working Capital Adjustment Due From Seller
WorkingCapitalAdjustmentDueFromSeller
0
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
341000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0
cvsi Goodwill On Acquisition
GoodwillOnAcquisition
365000
cvsi Goodwill On Acquisition
GoodwillOnAcquisition
0
cvsi Common Stock Consideration
CommonStockConsideration
700000
cvsi Common Stock Consideration
CommonStockConsideration
0
cvsi Contingent Consideration
ContingentConsideration
0
cvsi Contingent Consideration
ContingentConsideration
0
cvsi Cash Paid For Acquisition
CashPaidForAcquisition
6000
cvsi Cash Paid For Acquisition
CashPaidForAcquisition
0
cvsi Liquidity Considerations Policy Policytextblock
LiquidityConsiderationsPolicyPolicytextblock
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity Considerations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> - U.S. GAAP requires management to assess a company's ability to continue as a going concern for a period of one year from the financial statement issuance date and to provide related note disclosure in certain circumstances. The accompanying financial statements and notes have been prepared assuming the Company will continue as a going concern. The Company generated negative cash flows from operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the nine months ended September 30, 2024 and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">86.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of September 30, 2024. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives and to continue to make and implement strategic cost reductions, including reductions in employee headcount, vendor spending, and delaying expenses related to its drug development activities. The Company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2024, the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under a Secured Promissory Note with Streeterville Capital, LLC, a Utah limited liability company ("Streeterville") - refer to Note 6 for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to pursue the actions outlined above, as well as work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability.</span></p>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-700000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> - The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, valuation of inventory and assumptions related to revenue recognition.</span></p>
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3865000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4089000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12203000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2682000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2892000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1174000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1181000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1164000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1582000
CY2024Q3 us-gaap Inventory Gross
InventoryGross
5020000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
5655000
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
522000
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
522000
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1407000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1388000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1493000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1512000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3422000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3422000
CY2023Q4 us-gaap Goodwill
Goodwill
342000
cvsi Goodwill Acquisition Of Elevated Softgels
GoodwillAcquisitionOfElevatedSoftgels
465000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
8000
CY2024Q3 us-gaap Goodwill
Goodwill
815000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
116000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
78000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-16000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1000
us-gaap Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss
IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
3000
CY2023 us-gaap Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss
IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
1000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
103000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
78000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
78000
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
38000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16000
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
3000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
103000
CY2024Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
29357
us-gaap Operating Lease Cost
OperatingLeaseCost
86380
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
35657
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
35657
us-gaap Short Term Lease Cost
ShortTermLeaseCost
59429
us-gaap Variable Lease Cost
VariableLeaseCost
59429
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
35000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
59000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
94000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
92000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
92000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
92000
CY2024Q3 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
743000
CY2023Q4 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
254000
cvsi Cares Act Term For Repayment Of Debt Instrument To Avoid Penalty
CARESActTermForRepaymentOfDebtInstrumentToAvoidPenalty
P90D
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10750000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10750000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24435000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.32
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
14100000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.05
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
11687000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.42
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26848000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
56000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9642000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.3
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
33000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
26848000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
56000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.381
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.038
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.04
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44348000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41685000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44348000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41685000
CY2024Q3 cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0
cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0
CY2023Q3 cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0
cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-127040-index-headers.html Edgar Link pending
0000950170-24-127040-index.html Edgar Link pending
0000950170-24-127040.txt Edgar Link pending
0000950170-24-127040-xbrl.zip Edgar Link pending
cvsi-20240930.htm Edgar Link pending
cvsi-20240930.xsd Edgar Link pending
cvsi-ex31_1.htm Edgar Link pending
cvsi-ex31_2.htm Edgar Link pending
cvsi-ex32_1.htm Edgar Link pending
cvsi-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cvsi-20240930_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending